Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  LifeVantage Corporation    LFVN

LIFEVANTAGE CORPORATION

(LFVN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

LifeVantage Corp : Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in LifeVantage Corporation of Class Action Lawsuit and Upcoming Deadline - LFVN

share with twitter share with LinkedIn share with facebook
10/14/2016 | 09:12pm EDT

NEW YORK, NY / ACCESSWIRE / October 14, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against LifeVantage Corporation ("LifeVantage" or the "Company") (NASDAQ: LFVN) and certain of its officers. The class action, filed in United States District Court, District of Utah, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired LifeVantage securities between November 4, 2015 and September 13, 2016 both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act").

If you are a shareholder who purchased LifeVantage securities during the Class Period, you have until November 14, 2016 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

[Click here to join this class action]

LifeVantage identifies, researches, develops, and distributes nutraceutical dietary supplements and skin care products. LifeVantage Corporation sells its products through a network of independent distributors and preferred customers in the United States, Japan, Hong Kong, Australia, Canada, the Philippines, Mexico, and Thailand. The Company also sells its products online.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) LifeVantage lacked effective internal financial controls; (ii) as a result, the Company had improperly accounted for sales in certain international markets, along with associated revenue and income tax accruals; and (iii) as a result of the foregoing, LifeVantage's public statements were materially false and misleading at all relevant times.

On September 13, 2016, post-market, LifeVantage issued a press release and filed a Current Report on Form 8-K with the Securities and Exchange Commission, announcing a delay in the release of the Company's fourth quarter and fiscal year 2016 financial results, citing an internal review "relate[d] to sales of the Company's products in certain international markets and the determination of revenue and the deductibility of commission and incentive expenses associated with such sales, as well as the policies and procedures related to sales in those specific markets."

On this news, LifeVantage stock fell $1.32, or 12.69%, to close at $9.08 on September 14, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

© Accesswire 2016

share with twitter share with LinkedIn share with facebook
All news about LIFEVANTAGE CORPORATION
10/20LIFEVANTAGE : to Announce First Quarter Fiscal Year 2021 Results on November 3, ..
AQ
10/20LifeVantage to Announce First Quarter Fiscal Year 2021 Results on November 3,..
GL
09/08LIFEVANTAGE CORP : Change in Directors or Principal Officers (form 8-K)
AQ
09/08LIFEVANTAGE : Announces Management Transition
AQ
09/08LifeVantage Announces Management Transition
GL
08/27LifeVantage to Participate in Upcoming Investor Conferences
GL
08/18LIFEVANTAGE : Fiscal 4Q Earnings Snapshot
AQ
08/18LIFEVANTAGE CORP : Results of Operations and Financial Condition (form 8-K)
AQ
08/18LIFEVANTAGE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
08/18LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Fu..
GL
More news
Financials (USD)
Sales 2020 233 M - -
Net income 2020 11,5 M - -
Net cash 2020 21,0 M - -
P/E ratio 2020 17,1x
Yield 2020 -
Capitalization 167 M 167 M -
EV / Sales 2019 0,75x
EV / Sales 2020 0,74x
Nbr of Employees -
Free-Float 92,0%
Chart LIFEVANTAGE CORPORATION
Duration : Period :
LifeVantage Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LIFEVANTAGE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Managers
NameTitle
Steven R. Fife President, Chief Executive & Financial Officer
Garry M. Mauro Chairman
Charles J. Wach Chief Operating Officer
Brian Dixon Senior Vice President-Research & Development
Michael A. Beindorff Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LIFEVANTAGE CORPORATION-24.47%168
JOHNSON & JOHNSON-1.30%379 007
ROCHE HOLDING AG-4.55%282 543
PFIZER INC.-3.22%210 717
MERCK & CO., INC.-13.32%199 405
NOVARTIS AG-16.94%185 381